Dizal (Jiangsu) Pharmaceutical Future Growth
Future criteria checks 2/6
Dizal (Jiangsu) Pharmaceutical is forecast to grow earnings and revenue by 44% and 46.6% per annum respectively while EPS is expected to grow by 44.5% per annum.
Key information
44.0%
Earnings growth rate
44.5%
EPS growth rate
| Biotechs earnings growth | 38.8% |
| Revenue growth rate | 46.6% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 07 May 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1,903 | -164 | 57 | -172 | 3 |
| 12/31/2025 | 886 | -699 | -795 | -713 | 3 |
| 12/31/2024 | 401 | -1,014 | -1,235 | -1,075 | 3 |
| 3/31/2024 | 173 | -1,092 | -929 | -891 | N/A |
| 12/31/2023 | 91 | -1,108 | -1,000 | -968 | N/A |
| 9/30/2023 | 40 | -1,055 | -885 | -851 | N/A |
| 6/30/2023 | N/A | -905 | -801 | -763 | N/A |
| 3/31/2023 | N/A | -794 | -714 | -634 | N/A |
| 12/31/2022 | N/A | -736 | -677 | -603 | N/A |
| 9/30/2022 | 4 | -714 | -648 | -575 | N/A |
| 6/30/2022 | 7 | -716 | -600 | -532 | N/A |
| 3/31/2022 | 10 | -716 | -549 | -537 | N/A |
| 12/31/2021 | 10 | -670 | -501 | -492 | N/A |
| 9/30/2021 | 11 | -593 | -434 | -429 | N/A |
| 12/31/2020 | 28 | -587 | -622 | -410 | N/A |
| 12/31/2019 | 41 | -446 | -379 | -366 | N/A |
| 12/31/2018 | 39 | -174 | -149 | -136 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 688192 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 688192 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 688192 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 688192's revenue (46.6% per year) is forecast to grow faster than the CN market (13.6% per year).
High Growth Revenue: 688192's revenue (46.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 688192's Return on Equity is forecast to be high in 3 years time